Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Phase 1

Active, not recruiting

Conditions: Secondary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Glycosylated Recombinant Human G-CSF AVI-014
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-18

Last Posted Date: 2024-10-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 22

Registration Number: NCT03118492

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Angioimmunoblastic T-Cell Lymphoma
Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Adult T-Cell Leukemia/Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Prednisone

First Posted Date: 2017-04-13

Last Posted Date: 2024-02-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT03113500

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 2 locations

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Phase 1

Conditions: Hematopoietic/Lymphoid Cancer
Refractory Chronic Lymphocytic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
B-cell Chronic Lymphocytic Leukemia

Interventions: Biological: anti-CD19 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-04-12

Last Posted Date: 2019-11-27

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 20

Registration Number: NCT03110640

Locations: 🇨🇳
The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: Lorlatinib
Drug: Cyclophosphamide
Drug: Topotecan
Drug: Filgrastim/pegfilgrastim

First Posted Date: 2017-04-11

Last Posted Date: 2024-02-09

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 65

Registration Number: NCT03107988

Locations: 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇺🇸
Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 10 locations

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory B Acute Lymphoblastic Leukemia
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Other: Pharmacological Study

First Posted Date: 2017-04-07

Last Posted Date: 2024-04-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT03103971

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma

Interventions: Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-04-07

Last Posted Date: 2025-01-06

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 159

Registration Number: NCT03105336

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 16 locations

Treatment of Adult-Onset Immunodeficiency With Bortezomib

Phase 2

Conditions: Adult-onset Immunodeficiency

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide

First Posted Date: 2017-04-06

Last Posted Date: 2017-04-06

Lead Sponsor: Mahidol University

Target Recruit Count: 5

Registration Number: NCT03103555

Locations: 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase 1

Conditions: B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CART-19

First Posted Date: 2017-04-05

Last Posted Date: 2017-04-05

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT03101709

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Stage III Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Breast Inflammatory Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Metastatic Breast Carcinoma
Locally Advanced Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Cyclophosphamide
Drug: Neratinib
Drug: Doxorubicin
Drug: Paclitaxel
Biological: Trastuzumab
Biological: Pertuzumab

First Posted Date: 2017-04-05

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT03101748

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy